Share Name Share Symbol Market Type Share ISIN Share Description
Plant Health Care Plc LSE:PHC London Ordinary Share GB00B01JC540 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -0.5% 9.875 10,000 16:35:26
Bid Price Offer Price High Price Low Price Open Price
9.35 10.40 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 4.85 -2.90 -1.51 17
Last Trade Time Trade Type Trade Size Trade Price Currency
13:58:31 O 10,000 9.40 GBX

Plant Health Care (PHC) Latest News

More Plant Health Care News
Plant Health Care Takeover Rumours

Plant Health Care (PHC) Discussions and Chat

Plant Health Care (PHC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-10 12:58:329.4010,000940.00O
View all Plant Health Care trades in real-time

Plant Health Care (PHC) Top Chat Posts

Plant Health Care Daily Update: Plant Health Care Plc is listed in the Chemicals sector of the London Stock Exchange with ticker PHC. The last closing price for Plant Health Care was 9.93p.
Plant Health Care Plc has a 4 week average price of 9.25p and a 12 week average price of 5.88p.
The 1 year high share price is 15.50p while the 1 year low share price is currently 4.28p.
There are currently 172,822,881 shares in issue and the average daily traded volume is 95,279 shares. The market capitalisation of Plant Health Care Plc is £17,066,259.50.
dubai123: I think we need to give Chris Richards a chance. He is an honest guy with the right intentions and whilst the news flow of late has not matched the expectations set there are mitigating reasons to consider He is well aligned financially having invested in a personal capacity with hard cash . To me that shows believe and whilst the share price is painful to all the business has fantastic potential and we should be honest in our criticism but mindful we show support.The large volume the other day by the way of 2.3 million shares was a fund to fund switch with no change of owner
wan: Glad I read the signals correctly and sold out completely a while ago (even if a bit late!). The share price deserves a significant discount to be applied for a terrible, but reliable, track record! As for what I think of Chris Richards, Executive Chairman of PHC, I had better not print it! But suffice to say he is reliably best!
pugugly: Looks like bad news leaking - Share price in continuing fall. Could we have another Plant Impact on our hands - Over seduction by a major and then screwed royally? Could the Chairman's association with NANO another serial promiser but delivery failure (to date) be a --------------?? Thoughts ? OK In a much needed area if the world's growing population to be nourished but will investors ever see a reasonable return or is it time to salvage what one can?
riddlerone: Sorry should have made that clearer Sarossa holding bought by Mr Griffiths
pugugly: riddlerone: > Remember the last placing where RG bought many of his shares was at 10P Not sure how much he will need to clear cost of previous acquisitions - RG acquisition notice Current positions of top 2 holders who will dictate action are Name Shares Held Percent of Issued Share Capital* Richard Griffiths 56,560,632 38.26% Lombard Odier Asset Management (Europe) Limited 35,378,401 29.93% Figures are as at As at 30 August 2017,
skyship: 24p!!! - Be very careful newcomers - note the massively dilutive placing going through at a mere 10p!
thomasthetank1: Read Liberum's note on Plant Health Care (PHC), out this morning, by visiting … “FY15 sales +9% (+15% in l.c.) with gross margins jumping to 62% from 51% last year with better product mix. A doubling R&D led to higher opex driving FY net loss to $8m vs. $6m in FY14. Net cash ended FY15 at $8.4m vs. $16.6m last year. Looking ahead we are not changing estimates materially. We expect further sales growth in existing products and R&D ramp up. PHC is excited by R&D progress and expects to introduce a 2nd peptide family for evaluation this year with trials for the 1st peptide family (Innatus 3G) going well. Innatus 3G license auctions are now expected in 2017/18. Licenses for its other peptide technologies are targeted earlier than this. We believe the recent share price fall is vastly overdone...”
19wizard: Any further news/views on the sharp decline in the share price since May.On the surface it will look buy at 50p.Sure there are some powerful reasons for the decline.
bobdouthwaite: "10:05 UK, 18th January 2011, by Plant Health Care revamp ties fortunes to Monsanto Plant Health Care's exit from direct sales has increased its vulnerability to setbacks at key customer Monsanto, whose slow seed revenues last spring prompted the alternative agrichemicals group to warn on its results. Plant Health Care revealed on Friday that it was pulling back from parts of its historic strategy, including direct sales, to focus on licensing deals it sees as a more lucrative revenue source. "If they want to get their products out to as many acres as possible, direct sales isn't really going to achieve that," a person familiar with the company's thinking told However, the company for now has a limited roster of licensees – albeit including big names such as Syngenta - for its products, which aim to enhance a plant's own capabilities to see off pests or take up nutrients. Plant Health Care's fortunes appear particularly tied to Monsanto, the world's biggest seeds group, which has a deal to apply the Harpin plant protection product as a seed treatment. 'Key to sentiment' "The key near-term share price driver is the rate at which revenues from Monsanto pick up over next quarter, which is the main selling period for soybean seeds," Evolution analyst Philip Sparks said. "Newsflow from Monsanto... will be key to sentiment." Indeed, Plant Health Care's shares could "meander" until data is forthcoming from Monsanto, whose slow sales last spring prompted the London-listed company to warn revenues would miss targets, sending the stock down by more than one-third. Investors have higher hopes for Monsanto this year, following a revamp of its pricing structure, and with strong crop prices improving farmers' willingness to splash out on genetically-enhanced seed. Monsanto shares have rebounded more than 50% from a nadir in late September. Mr Sparks kept a "buy" rating on Plant Health Care shares with a price target of 1650p. US disposal Plant Health Care's strategic revamp has involved the disposal of a US landscape and retail business which had been in part viewed as a way of enhancing direct sales. However, the business, sold for $4.65m, has been hit by the downturn in the US housing market, seeing operating profits drop to some $400,000 in the last financial year. "Investors attach little value to Plant Health Care's products businesses," Mr Sparks said. "The [group's] long term prospects are unaffected by the sale." Plant Health Care shares stood unchanged at 74.5p in morning deals" A price target of 1650p...I think not!
bobdouthwaite: Fwiw Monsanto's share price has fallen almost 40% since the beginning of the year, suggesting hard times for agribusiness more widely at the moment. I'm sure they did their due diligence with Harpin, but why would farmers pay for higher yielding Roundup Ready when soyabean futures look so poor?
Plant Health Care share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Plant Heal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200811 04:06:49